ASCO 2025 | ASCO 2025 lung cancer updates: DeLLphi-304 & cost-effective IO infusions

What is the plenary for lung cancer? We don’t have a plenary for lung cancer this year, which is unusual because we’re getting plenaries every year. But I do think that we are fulfilling some unmet needs right here at ASCO. I think for me the highlight in lung cancer, of course, is the small cell trial with tarlatamab. We got the DeLLphi-304 , it’s going to be presented this afternoon, but we got the publication online in the New England Journal already. The trial that provided overall survival of over 12 months and second line and we know that in first line right now the overall survival with chemo-immune therapy with Atezolizumab or tarlatamabit’s about 12 months so a second line trial outperforming the first line trial it’s an unmet need for the patients and this for me it’s quite interesting so we’re also talking about some very interesting data this afternoon I think the best is yet to come we’re recording this at this today’s Monday right so at Monday afternoon is going to be, I think, the best day for us, but we got the data from the new oral trial, osimertinib plus chemotherapy for patients that could be resectable. And I think this is also, and I met need, a very controversial study with the data we have published on JCO. Not as good as we wanted to, but I think basically it’s this. But for me, the largest highlight was hidden into a session, a rapid oral abstract session that was presented this morning actually talking about time of day for infusions of immune therapy. Patients who were receiving infusions before 3 p.m. had a better result. And it’s huge, like huge, major difference. And it costs like nothing. You just have to change your patient for the morning. The patient doesn’t have to wake up at 5 a.m. It can be like noon for having infusions. There’s a major, major difference. and both PFS and overall survival. So I think this should be this would be my plenary for the for the ASCO. Just changing the hour of infusion they showed like the lymphocyte profiles they change over time with with the infusion early in the morning maybe because of circadian rhythm and this for me would be the greatest thing in ASCO because it’s it’s cheap and you can have a great impact in your patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.